(NHI) National Health Investors - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US63633D1046
NHI: Senior Housing, Nursing Facilities, Hospitals, Retirement Communities
National Health Investors, Inc. (NYSE:NHI), established in 1991, stands as a prominent real estate investment trust (REIT) focused on the healthcare sector. NHIs strategy revolves around acquiring and financing properties that cater to senior housing and medical facilities, leveraging a diverse approach to mitigate risks. Their investment tactics include sale-leaseback transactions, joint ventures, and providing mortgage and mezzanine financing, which not only diversifies their portfolio but also ensures a steady income stream through rents.
NHIs portfolio is a testament to their strategic diversification, encompassing a range of facilities such as independent living communities, assisted living and memory care units, entrance-fee retirement communities, skilled nursing facilities, and specialty hospitals. This diversification is crucial as it spreads investment risk across different types of healthcare properties, ensuring stability even when certain sectors experience fluctuations. The aging population in the U.S. underscores a growing demand for such facilities, positioning NHI favorably in a growth-oriented market.
From a financial standpoint, NHI boasts a market capitalization of approximately $3.1 billion, reflecting its substantial presence in the REIT sector. The current P/E ratio of 23.63 indicates that investors are valuing the company based on its earnings potential, while the forward P/E of 12.84 suggests anticipation of future growth. The price-to-book ratio of 2.54 highlights that investors are willing to pay a premium over the book value, likely due to confidence in NHIs management and growth prospects. These metrics, coupled with the companys diversified portfolio, make NHI an attractive consideration for investors seeking exposure to the healthcare real estate market.
Additional Sources for NHI Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
NHI Stock Overview
Market Cap in USD | 3,413m |
Sector | Real Estate |
Industry | REIT - Healthcare Facilities |
GiC Sub-Industry | Health Care REITs |
IPO / Inception | 1991-10-09 |
NHI Stock Ratings
Growth 5y | 61.0% |
Fundamental | 32.1% |
Dividend | 42.1% |
Rel. Strength | 13.3 |
Analysts | 3.88/5 |
Fair Price Momentum | 76.49 USD |
Fair Price DCF | 101.45 USD |
NHI Dividends
Dividend Yield 12m | 4.98% |
Yield on Cost 5y | 11.36% |
Annual Growth 5y | -3.99% |
Payout Consistency | 93.8% |
NHI Growth Ratios
Growth Correlation 3m | 81% |
Growth Correlation 12m | 45.8% |
Growth Correlation 5y | 55% |
CAGR 5y | 18.41% |
CAGR/Max DD 5y | 0.58 |
Sharpe Ratio 12m | 1.77 |
Alpha | 18.67 |
Beta | 1.116 |
Volatility | 23.08% |
Current Volume | 303.8k |
Average Volume 20d | 241.7k |
As of April 03, 2025, the stock is trading at USD 73.77 with a total of 303,835 shares traded.
Over the past week, the price has changed by +0.74%, over one month by +1.81%, over three months by +9.20% and over the past year by +28.48%.
Neither. Based on ValueRay Fundamental Analyses, National Health Investors is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 32.14 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NHI as of April 2025 is 76.49. This means that NHI is currently overvalued and has a potential downside of 3.69%.
National Health Investors has received a consensus analysts rating of 3.88. Therefor, it is recommend to buy NHI.
- Strong Buy: 3
- Buy: 1
- Hold: 4
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, NHI National Health Investors will be worth about 85 in April 2026. The stock is currently trading at 73.77. This means that the stock has a potential upside of +15.17%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 82.1 | 11.3% |
Analysts Target Price | 79.6 | 7.9% |
ValueRay Target Price | 85 | 15.2% |